Securities and Exchange Commission
Washington, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
ASLAN Pharmaceuticals Limited
(Name of Issuer)
Ordinary Shares as represented by American Depository Shares (“ADSs”),
par value $0.01 per ordinary share**
(Title of Class of Securities)
04522R101***
(CUSIP Number)
April 11, 2022
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
ý Rule 13d-1(c)
o Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
**Ordinary Shares are not for trading, but only in connection with the registration of the ADSs.
***CUSIP number assigned to the ADSs of the Company. Each ADS represents five Ordinary Shares.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| Page 1 of 8 |
|
CUSIP No. 04522R101 |
13G | Page 2 of 8 Pages |
| 1 |
NameS of
Reporting Persons
TANG CAPITAL PARTNERS, LP
|
||||
| 2 | Check the Appropriate Box if a Member of a Group* (a) ¨ (b) ý |
||||
| 3 | SEC Use Only |
||||
| 4 |
Citizenship or Place of Organization
DELAWARE
|
||||
|
Number of |
5 |
Sole Voting Power 0
|
|||
|
Shares BENEFICIALLY |
6 |
Shared Voting Power
18,796,125 |
|||
| Each Reporting Person with |
7 |
Sole Dispositive Power
0
|
|||
| 8 |
Shared Dispositive Power
18,796,125
|
||||
| 9 |
Aggregate Amount Beneficially Owned by each Reporting Person
18,796,125
|
||||
| 10 |
Check Box if the Aggregate Amount in Row (9) excludes certain shares
¨ |
||||
| 11 |
Percent of Class represented by amount in row 9
5.4%
|
||||
| 12 |
type of reporting person
pN
|
||||
| Page 2 of 8 |
|
CUSIP No. 04522R101 |
13G | Page 3 of 8 Pages |
| 1 |
NameS of
Reporting Persons
Tang Capital Management, LLC
|
||||
| 2 | Check the Appropriate Box if a Member of a Group* (a) ¨ (b) ý |
||||
| 3 | SEC Use Only |
||||
| 4 |
Citizenship or Place of Organization
DELAWARE
|
||||
|
Number of |
5 |
Sole Voting Power 0
|
|||
|
Shares BENEFICIALLY |
6 |
Shared Voting Power
18,796,125 |
|||
| Each Reporting Person with |
7 |
Sole Dispositive Power
0
|
|||
| 8 |
Shared Dispositive Power
18,796,125
|
||||
| 9 |
Aggregate Amount Beneficially Owned by each Reporting Person
18,796,125
|
||||
| 10 |
Check Box if the Aggregate Amount in Row (9) excludes certain shares
¨ |
||||
| 11 |
Percent of Class represented by amount in row 9
5.4%
|
||||
| 12 |
type of reporting person
OO
|
||||
| Page 3 of 8 |
|
CUSIP No. 04522R101 |
13G | Page 4 of 8 Pages |
| 1 |
NameS of
Reporting Persons
Kevin Tang
|
||||
| 2 | Check the Appropriate Box if a Member of a Group* (a) ¨ (b) ý |
||||
| 3 | SEC Use Only |
||||
| 4 |
Citizenship or Place of Organization
united states
|
||||
|
Number of |
5 |
Sole Voting Power 0
|
|||
|
Shares BENEFICIALLY |
6 |
Shared Voting Power
18,796,125 |
|||
| Each Reporting Person with |
7 |
Sole Dispositive Power
0
|
|||
| 8 |
Shared Dispositive Power
18,796,125
|
||||
| 9 |
Aggregate Amount Beneficially Owned by each Reporting Person
18,796,125
|
||||
| 10 |
Check Box if the Aggregate Amount in Row (9) excludes certain shares
¨ |
||||
| 11 |
Percent of Class represented by amount in row 9
5.4%
|
||||
| 12 |
type of reporting person
IN
|
||||
| Page 4 of 8 |
| Item 1(a). | Name of Issuer: |
ASLAN Pharmaceuticals Limited, a Delaware corporation (the “Issuer”)
| Item 1(b). | Address of Issuer’s Principal Executive Offices: |
83 Clemenceau Avenue #12-03 UE Square, Singapore 239920
| Item 2(a). | Name of Person Filing: |
This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.
| Item 2(b). | Address of Principal Business Office or, if none, Residence: |
4747 Executive Drive, Suite 210, San Diego, CA 92121
| Item 2(c). | Citizenship: |
Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.
| Item 2(d). | Title of Class of Securities: |
Ordinary Shares, par value $0.01 per share, represented by ADSs (the “Ordinary Shares”)
| Item 2(e). | CUSIP number 04522R101 has been assigned to the ADSs of the Company. Each ADS represents five Ordinary Shares. |
| Item 3. | Not applicable. |
| Item 4. | Ownership. |
| (a) | Amount Beneficially Owned: |
Tang Capital Partners. Tang Capital Partners beneficially owns 18,796,125 Ordinary Shares of the Issuer, in the form of 3,759,225 ADSs.
Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.
Tang Capital Management. Tang Capital Management beneficially owns 18,796,125 Ordinary Shares of the Issuer, in the form of 3,759,225 ADSs.
Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.
Kevin Tang. Kevin Tang beneficially owns 18,796,125 Ordinary Shares of the Issuer, in the form of 3,759,225 ADSs.
| Page 5 of 8 |
Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.
The percentages used herein are based on 348,723,365 Ordinary Shares outstanding as of December 31, 2021, as set forth in the Issuer’s Annual Report on Form 20-F that was filed with the Securities and Exchange Commission on March 25, 2022.
| (b) | Percent of Class: | |
| Tang Capital Partners | 5.4% | |
| Tang Capital Management | 5.4% | |
| Kevin Tang | 5.4% | |
| (c) | Number of shares as to which such person has: |
| (i) | sole power to vote or to direct the vote: | |
| Tang Capital Partners | 0 shares | |
| Tang Capital Management | 0 shares | |
| Kevin Tang | 0 shares |
| (ii) | shared power to vote or to direct the vote: | |
| Tang Capital Partners | 18,796,125 shares | |
| Tang Capital Management | 18,796,125 shares | |
| Kevin Tang | 18,796,125 shares |
| (iii) | sole power to dispose or to direct the disposition of: | |
| Tang Capital Partners | 0 shares | |
| Tang Capital Management | 0 shares | |
| Kevin Tang | 0 shares |
| (iv) | shared power to dispose or to direct the disposition of: | |
| Tang Capital Partners | 18,796,125 shares | |
| Tang Capital Management | 18,796,125 shares | |
| Kevin Tang | 18,796,125 shares |
| Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
Not applicable
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. |
Not applicable.
| Item 8. | Identification and Classification of Members of the Group. |
Not applicable.
| Page 6 of 8 |
| Item 9. | Notice of Dissolution of Group. |
Not applicable.
| Item 10. | Certification. |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
| Page 7 of 8 |
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| Date: | April 21, 2022 | |
| TANG CAPITAL PARTNERS, LP | ||
| By: | Tang Capital Management, LLC, its General Partner | |
| By: | /s/ Kevin Tang | |
| Kevin Tang, Manager | ||
| TANG CAPITAL MANAGEMENT, LLC | ||
| By: | /s/ Kevin Tang | |
| Kevin Tang, Manager | ||
| /s/ Kevin Tang | ||
| Kevin Tang | ||
Page 8 of 8
Exhibit 99.1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Ordinary Shares, $0.01 par value per share, of ASLAN Pharmaceuticals Limited and further agree to the filing of this Joint Filing Agreement as an exhibit thereto. In addition, each party to this Joint Filing Agreement expressly authorizes each other party to this Joint Filing Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.
| Date: April 21, 2022 | TANG CAPITAL PARTNERS, LP |
|||
| By: | Tang Capital Management, LLC | |||
| Its: | General Partner | |||
| By: | /s/ Kevin Tang | |||
| Name: | Kevin Tang | |||
| Title: | Manager | |||
| TANG CAPITAL MANAGEMENT, LLC |
||||
| By: | /s/ Kevin Tang | |||
| Name: | Kevin Tang | |||
| Title: | Manager | |||
| /s/ Kevin Tang | ||||
| Name: | Kevin Tang | |||